Scinopharm Taiwan | Sustainability Performance
Provides active pharmaceutical ingredients and contract development and manufacturing services, focusing on oncology, central nervous system, and other specialized therapeutic fields.
1997
Taiwan
1,001 - 5,000 employees
Pharmaceuticals
$100M - 500M in revenue
$1M - 10M in profitability
Sustainability Ranking & Industry Benchmark
#2930
Overall#40
in Taiwan#67
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
Revenue & EBITDA
$101.5MFY2025 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
15.7%FY2025
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
1.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.1
20230.1
▲ 14.3%
0.1
▼ 2.0%
Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Available
Human rights policy
Available
Recycling policy
Available
Workplace health & safety policy
Available
21%
Independent Directors
5 out of 24 incl. management
Overall score
80
Environment
99
Social
99
Governance
43
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
